"Receptors, CXCR4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
CXCR receptors with specificity for CXCL12 CHEMOKINE. The receptors may play a role in HEMATOPOIESIS regulation and can also function as coreceptors for the HUMAN IMMUNODEFICIENCY VIRUS.
| Descriptor ID |
D019718
|
| MeSH Number(s) |
D12.776.543.750.695.160.500.400 D12.776.543.750.705.852.125.500.400 D12.776.543.750.830.700.650
|
| Concept/Terms |
Receptors, CXCR4- Receptors, CXCR4
- LESTR Receptor
- CXC Chemokine Receptor 4
- Fusin
- CXCR4 Receptor
- Receptor, CXCR4
- CXCR4 Receptors
- Leukocyte-Derived Seven-Transmembrane Domain Receptor
- Leukocyte Derived Seven Transmembrane Domain Receptor
- Receptor, LESTR
|
Below are MeSH descriptors whose meaning is more general than "Receptors, CXCR4".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Chemokine [D12.776.543.750.695.160]
- Receptors, CXCR [D12.776.543.750.695.160.500]
- Receptors, CXCR4 [D12.776.543.750.695.160.500.400]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Chemokine [D12.776.543.750.705.852.125]
- Receptors, CXCR [D12.776.543.750.705.852.125.500]
- Receptors, CXCR4 [D12.776.543.750.705.852.125.500.400]
- Receptors, Virus [D12.776.543.750.830]
- Receptors, HIV [D12.776.543.750.830.700]
- Receptors, CXCR4 [D12.776.543.750.830.700.650]
Below are MeSH descriptors whose meaning is more specific than "Receptors, CXCR4".
This graph shows the total number of publications written about "Receptors, CXCR4" by people in this website by year, and whether "Receptors, CXCR4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 3 | 1 | 4 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 7 | 0 | 7 |
| 2005 | 6 | 1 | 7 |
| 2006 | 4 | 2 | 6 |
| 2007 | 4 | 4 | 8 |
| 2008 | 9 | 2 | 11 |
| 2009 | 5 | 5 | 10 |
| 2010 | 4 | 3 | 7 |
| 2011 | 5 | 0 | 5 |
| 2012 | 2 | 3 | 5 |
| 2013 | 7 | 4 | 11 |
| 2014 | 5 | 7 | 12 |
| 2015 | 5 | 6 | 11 |
| 2016 | 4 | 4 | 8 |
| 2017 | 3 | 6 | 9 |
| 2018 | 3 | 3 | 6 |
| 2019 | 2 | 3 | 5 |
| 2020 | 5 | 2 | 7 |
| 2021 | 6 | 2 | 8 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, CXCR4" by people in Profiles.
-
Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Gastroenterology. 2024 Jul; 167(2):298-314.
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res. 2023 06 06; 25(1):62.
-
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia. 2023 06; 37(6):1379-1383.
-
Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients. J Clin Immunol. 2022 11; 42(8):1748-1765.
-
A British view on the management of Waldenstr?m macroglobulinemia. Br J Haematol. 2022 04; 197(2):133-134.
-
CXC chemokine receptor 4 (CXCR4) targeted gold nanoparticles potently enhance radiotherapy outcomes in breast cancer. Nanoscale. 2021 Nov 25; 13(45):19056-19065.
-
Venetoclax in Previously Treated Waldenstr?m Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71.
-
Multicenter Experience of Hematopoietic Stem Cell Transplantation in WHIM Syndrome. J Clin Immunol. 2022 01; 42(1):171-182.
-
How to Sequence Therapies in Waldenstr?m Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92.
-
Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenstr?m macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253.